Search Results for “research” – Page 2 – media

International researchers use shear waves to map blood vessel structures

Researchers from King’s College London’s (KCL) School of Biomedical Engineering and Imaging sciences, along with partners at the University of Michigan, the Institut national de la santé et de la recherche médicale in Paris, Norway and Germany, are using shear waves to map blood vessel structures to improve treatments for tumours and other medical conditions. Findings published in Science Advances could improve cancer treatment and potentially improve drug delivery while helping researchers better understand tumours. Michigan and KCL experts developed a new theory using MRI-based elastography imaging to study how shear waves travel through tissue. By analysing them, researchers are able to measure the architecture of blood vessels non-invasively using readily available clinical imaging devices. Shear waves store information about the materials they pass through, including tissue stiffness, which can help diagnose diseases. The method allows researchers to see tiny blood vessels that are usually too small to detect and ...
- Source: drugdu
- 57
- August 16, 2024
CMT Research Foundation invests in research project to develop treatments for CMTs

The CMT Research Foundation (CMTRF) has invested in a research project based at Nationwide Children’s Hospital, US, to develop new vehicles for delivering gene therapies to treat several types of Charcot-Marie-Tooth disease (CMT). The new project aims to improve the treatment efficacy and safety of gene therapies for forms of CMTs, including CMT1A, the most prevalent form, which accounts for 50% of all patients with nerve-damaging disorder. Recognised as a rare peripheral neuropathy disease that affects nearly three million people globally, CMT is a group of inherited conditions that damage the peripheral nerves, which are found outside the main central nervous system. The development of safe and effective gene therapies for CMT requires the delivery of a therapeutic genetic payload into the peripheral nervous system, which specifically targets Schwann cells, a type of glial cells that help form the myelin sheath around the nerve fibres, for types of CMT including ...
- Source: drugdu
- 88
- August 15, 2024
KCL and UCL scientists develop accurate AI brain imaging model for research

Researchers from King’s College London have developed a new artificial intelligence (AI) brain imaging model in collaboration with University College London (UCL) which is realistic and accurate enough to use in medical research. Published in Nature Medicine Intelligence, the three-dimensional, synthetic images of the human brain could help support research to predict, diagnose and treat brain diseases including dementia, stroke and multiple sclerosis. According to Brain Research UK, there are an estimated 11 million people in the UK who are living with a neurological condition. Among the most common are Alzheimer’s disease, epilepsy and stroke. In collaboration with the London Medical Imaging and AI Centre for Value-Based Healthcare and NVIDIA data scientists and engineers, researchers trained the AI model in weeks as opposed to months using the NVIDIA Cambridge-1 supercomputer. The model is able to produce 3D, high-resolution images that have all the characteristics of real human brains, including correct ...
- Source: drugdu
- 80
- August 13, 2024
MRC and MND Association award £3.9m to KCL and UCL for ALS/FTD research

The Medical Research Council and the Motor Neurone Disease (MND) Association have awarded researchers from King’s College London (KCL) and University College London (UCL) £3.9m to investigate an early disease pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The team aims to explore and systematically investigate the axonal dysfunction in neurodegeneration and design therapeutic strategies to address the disease at an early stage. Axonal dysfunction occurs when there is a complete degeneration of axons – parts of the neurons that allow them to carry signals and transmit information to other cells. These results are seen in neurodegenerative diseases such as ALS and FTD. ALS is a fatal type of MND that causes progressive degeneration of nerve cells in the spinal cord and brain, while FTD is the result of damage to neurons in the frontal and temporal lobes of the brain. Combined, these conditions are estimated to affect ...
- Source: drugdu
- 73
- August 9, 2024
BHF’s HIF funds five heart research projects over £800,000

The British Heart Foundation (BHF) has awarded five research projects more than £800,000 as part of its Healthcare Innovation Awards to improve the delivery of vital healthcare for patients. Comprising artificial intelligence (AI) and stethoscopes to offer digital access to mental health services to those living in remote areas, the projects will receive between £100,000 and £300,000 via the Healthcare Innovation Fund (HIF). Cardiovascular diseases (CVD) affect around seven million people in the UK, including coronary heart disease, the most common form of heart and circulatory disease, which affects around 2.3 million people in the UK. The HIF supports research that aims to explore and improve existing services and care for people living with heart conditions across the UK. Researchers from Imperial College London, Hull York Medical School, Leicester University Hospital, Jubilee University National Hospital and the University Hospital of Wales have been selected to receive the funding. The research ...
- Source: drugdu
- 62
- August 8, 2024
Researchers reveal brain parasites could be used to treat cognitive disorders

Researchers from the University of Glasgow, in collaboration with Tel Aviv University, along with international researchers, have revealed that brain parasites could be used to deliver drugs to the brain to treat cognitive disorders. In the study published in Nature Microbiology, researchers explored whether the common brain parasite Toxoplasma gondii could be used to deliver treatment across the blood-brain barrier, a major complication for the treatment of many neurological conditions. According to a study published in the Lancet Neurology in March and funded by the Bill & Melinda Gates Foundation, neurological conditions are considered the leading cause of ill health worldwide, with stroke, neonatal encephalopathy, migraine, Alzheimer’s disease (AD) and other dementias, and diabetic neuropathy being the biggest global contributors. Researchers engineered Toxoplasma gondii parasites to deliver the MeCP2 protein, a therapeutic protein that has been dubbed a promising target for Rett syndrome, a debilitating neurological disorder caused by mutations in ...
- Source: drugdu
- 61
- August 8, 2024
ETH Zurich researchers reveal how colorectal cancer cells colonise the liver

Researchers from ETH Zurich, Switzerland, have revealed how colorectal cancer cells colonise the liver, which could help to develop future treatments that can be a hindrance to the formation of often fatal metastases. The study published in Nature Cell was led by Andreas Moor, an assistant professor in the department of biosystems science and engineering at ETH Zurich. Currently the third most common cancer type worldwide and the second most common cause of cancer death, colorectal cancer, otherwise known as bowel cancer, occurs when abnormal cells start to divide and grow in an uncontrolled way in the large bowel and back passage. In most cases of fatal cancer, metastasis is the most likely cause, which occurs when the primary tumour has sent out cells and invaded other organs of the body. With no current treatment to prevent the metastatic process, researchers tested on genetically modified mice and discovered that a ...
- Source: drugdu
- 76
- August 7, 2024
Researchers reveal CAR-enhancer therapy could help overcome cancer relapse

Cancer is estimated to affect more than three million people living in the UK, according to Macmillan Cancer Support Researchers from the Dana-Farber Cancer Institute have revealed in a study that CAR-enhancer (CAR-E) therapy could help patients overcome cancer relapse. In the findings published in Nature Biotechnology, researchers report on a technique to prevent relapse and researchers hope to launch the first trial in the near future. It is estimated that there are more than three million people living in the UK with cancer, according to Macmillan Cancer Support, with breast cancer being the most prevalent, accounting for more than 55,000 new cases every year. A common challenge faced when using CAR T-cell therapies is that many patients, including those whose cancer has gone into full remission, eventually relapse. To eliminate this problem, the new techniques create what researchers consider a CAR-E therapeutic platform, which causes CAR T cells to ...
- Source: drugdu
- 110
- August 6, 2024
HDR UK and DPUK granted £2m for new motor neurone disease research initiative

The rapidly progressive neurological condition affects around 5,000 people in the UK Health Data Research UK (HDR UK) and Dementias Platforms UK (DPUK) have received £2m in funding to launch a new initiative to accelerate motor neurone disease research. Supported by the UK Dementia Research Institute, the MND Research Data Catalyst is funded by the Department of Health and Social Care and delivered through the National Institute of Health and Care Research (NIHR). Currently affecting around 5,000 people in the UK, MND is a fatal, rapidly progressing neurological condition caused by the accumulation of proteins in the brain that clump together to gradually stop cells from working. Supported by the UK government in partnership with charities and organisations including the NIHR, UK Research and Innovation, MND Association, My Name’5 Doddie Foundation, MND Scotland and LifeArc, along with the MND research community, the new initiative aims to accelerate the discovery of ...
- Source: drugdu
- 93
- August 3, 2024
NHS Scotland, AZ and Scottish universities partner for kidney health research

NHS Scotland, AstraZeneca (AZ) and the Universities of Glasgow and Dundee have entered into a partnership to accelerate research into treating chronic kidney disease (CKD). The collaboration aims to develop new medicines to slow down the progression of CKD, build infrastructure and enhance expertise in renal clinical trial delivery in Scotland to improve patient outcomes. Affecting nearly 850 million people worldwide, CKD is a serious, progressive condition caused by decreased kidney function, commonly caused by diabetes, hypertension and glomerulonephritis. By preventing the progression of CKD, patients will live longer, better lives, free from other consequences of the condition, including heart failure, cardiovascular disease and stroke, while also reducing pressure on the NHS. In addition to slowing the progression of CKD, NHS Scotland, AZ and the Universities of Glasgow and Dundee will work to reduce the risk of patients potentially needing dialysis, a procedure to remove waste products and excess fluid ...
- Source: drugdu
- 107
- August 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.